Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

A simplified prognostic system for resected pancreatic neuroendocrine neoplasms

(2010) Nikiforos Ballian et al.   HPB

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

(2009) Nathalie Theou-Anton et al.   DRUG SAFETY

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Interventional treatment of neuroendocrine liver metastases

(2009) U. Knigge et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

(2008) T. R. Halfdanarson et al.   ANNALS OF ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY